Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine whether, among smokers with elevated
depressive symptoms, sequential antidepressant pharmacotherapy with fluoxetine (20 mg) begun
8 weeks prior to and extended throughout standard smoking cessation treatment with
transdermal nicotine patch (ST-TNP) will result in superior short-and long-term smoking
cessation outcomes compared to sequential pharmacotherapy with placebo medication combined
with ST-TNP. The secondary aim of the study is to test the hypothesis that, among smokers
with elevated depressive symptoms, sequential treatment with fluoxetine will result in lower
levels of depressive symptoms and negative mood and higher levels of positive mood
immediately prior to and throughout the course of smoking cessation treatment relative to the
placebo condition.